News Sentiment

CLGN sentiment intelligence

Collplant Biotechnologies Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.37 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+8.2% over one week, +8.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend inactive 8.5% over four weeks
Fair value -89.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 24
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 6
simplywall.st 5
DonanımHaber 4
TradingKey 4
PR Newswire 3
Quantisnow 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 23
Market update 18
Deals and strategy 3
Analyst action 3
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Simply Wall Street Direct company coverage

CollPlant Biotechnologies (Nasdaq:CLGN) - Stock Analysis

This Simply Wall St analysis provides a comprehensive overview of CollPlant Biotechnologies (CLGN), a regenerative and aesthetic medicine company. It highlights a US$6.0m market cap, analyst target price of US$11.56, and significant risks including high share price volatility, de

Tone
Negative 37/100
Event
Analyst action
Published
06 May 2026 11:09
Source
Simply Wall Street
Stock Titan Direct company coverage

[EFFECT] CollPlant Biotechnologies Ltd SEC Filing

This article reports on an SEC Filing (Form EFFECT) by CollPlant Biotechnologies Ltd (NASDAQ: CLGN). The filing indicates a "Notice of Effectiveness" with an effectiveness date of April 21, 2026, at 4:30 P.M. The article details the company's CIK, file number, and provides links

Tone
Neutral 50/100
Event
Market update
Published
25 Apr 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

Half the staff cut as CollPlant resets after AbbVie ends deal

CollPlant (CLGN) has announced the termination of its development agreement with AbbVie, leading to a significant company-wide cost-reduction plan that includes a 50% workforce reduction. These measures are expected to extend the company's cash runway into Q4 2026. CollPlant is n

Tone
Negative 30/100
Event
Deals and strategy
Published
23 Apr 2026 17:10
Source
Stock Titan
Stock Titan Direct company coverage

CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares

CollPlant Biotechnologies Ltd. (CLGN) has registered 3.296 million ordinary shares for resale, stemming from the exercise of private placement and placement agent warrants issued in February 2026. The company will not receive proceeds from this resale, but could gain approximatel

Tone
Neutral 50/100
Event
Market update
Published
22 Apr 2026 05:09
Source
Stock Titan
Intellectia AI Direct company coverage

CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead

CollPlant has announced the termination of its development agreement with AbbVie, aiming to seek new strategic partners in the medical aesthetics market for 2026. The company is implementing a cost-reduction plan, including a 50% workforce cut, to extend its cash runway into Q4 2

Tone
Negative 41/100
Event
Deals and strategy
Published
13 Apr 2026 14:09
Source
Intellectia AI
Stock Titan Direct company coverage

AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50%

CollPlant (NASDAQ: CLGN) announced that AbbVie's Allergan Industrie SAS has terminated their 2021 development agreement for a dermal and soft tissue filler, effective June 8, 2026. In response, CollPlant is implementing a cost-reduction plan, including a 50% workforce cut, to ext

Tone
Negative 8/100
Event
Market update
Published
13 Apr 2026 11:40
Source
Stock Titan
Quantisnow Direct company coverage

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies received a notification from Nasdaq regarding its minimum bid requirement. This alert was sent to Quantisnow Plus members shortly after publication. The company's stock symbol is CLGN and it is categorized under Health Care.

Tone
Negative 39/100
Event
Market update
Published
12 Apr 2026 12:39
Source
Quantisnow
Stock Titan Direct company coverage

CLGN SEC Filings - Collplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms

This page on Stock Titan provides comprehensive access to SEC filings for Collplant Biotechnologies Ltd (CLGN), including annual reports (20-F), quarterly reports via 6-K submissions, and documentation of material events. It details the company's regulatory disclosures as a forei

Tone
Positive 64/100
Event
Regulatory and legal
Published
31 Mar 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale

CollPlant Biotechnologies (NASDAQ: CLGN) has registered 3.296 million ordinary shares for resale by existing selling shareholders. These shares are issuable upon the exercise of Private Placement Warrants from a February 2026 financing round. The company will not receive proceeds

Tone
Neutral 50/100
Event
Market update
Published
31 Mar 2026 08:40
Source
Stock Titan
Quantisnow Direct company coverage

CollPlant Biotechnologies Launches Redesigned Corporate Website

CollPlant Biotechnologies has launched a newly redesigned corporate website. This information was released via Quantisnow, a real-time market data and news platform specializing in aggregating financial information for retail investors. The article briefly mentions recent analyst

Tone
Positive 59/100
Event
Analyst action
Published
29 Mar 2026 07:10
Source
Quantisnow
Stock Titan Direct company coverage

CollPlant (Nasdaq: CLGN) 2025 revenue jumps on AbbVie milestone, loss narrows

CollPlant (Nasdaq: CLGN) reported a significant increase in 2025 GAAP revenue to $2.4 million, primarily driven by a $2 million milestone payment from AbbVie related to its dermal filler program. The company also managed to narrow its GAAP net loss to $11.5 million from $16.6 mil

Tone
Positive 65/100
Event
Earnings
Published
27 Mar 2026 23:40
Source
Stock Titan
PR Newswire Direct company coverage

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies announced its 2025 financial results, reporting increased GAAP revenues of $2.4 million, mainly driven by a $2 million payment from AbbVie for a development milestone. The company highlighted advancements across its rhCollagen platform, including the lau

Tone
Neutral 50/100
Event
Earnings
Published
27 Mar 2026 06:39
Source
PR Newswire